Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOdyssean Inves. Regulatory News (OIT)

Share Price Information for Odyssean Inves. (OIT)

Share Price is delayed by 15 minutes
Get Live Data
196.50    -2.50 (-1.26%)
Bid:
196.00
Ask:
199.50
Spread: 3.50 (1.786%)
Market Cap: £275.85m
OIT Live PriceLast checked at - London Stock Exchange

Intraday Odyssean Inves. Share Chart

Form 8.3 - NCC Group PLC

11 May 2026 10:53

RNS Number : 8093D
Harwood Capital Management Limited
11 May 2026
Β 

Β 

FORM 8.3

Β 

Β 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Full name of discloser:

Harwood Capital Management Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Odyssean Investment Trust Plc, Oryx International Growth Fund Limited, Harwood Capital LLP and North Atlantic Smaller Companies Investment Trust Plc are managed by the Harwood Capital Management Limited ("HCML") group of companies.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

NCC Group plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

8 May 2026

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

Β 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Β 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Β 

Class of relevant security:

Β 

1p Ordinary Shares

Β 

Β 

Interests

Short positions

Β 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

35,784,474

12.58%

Β 

Β 

(2) Cash-settled derivatives:

Β 

Β 

Β 

Β 

Β 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Β 

Β 

Β 

Β 

TOTAL:

35,784,474*

12.58%*

Β 

Β 

Β 

*Split of Holding

Β 

Interests

Entity

Number

%

Harwood Capital LLP

1,112,500

0.39%

North Atlantic Smaller Companies Investment Trust Plc

8,235,528

2.89%

Oryx International Growth Fund Limited

4,436,446

1.56%

Odyssean Investment Trust PLC

22,000,000

7.73%

Β 

Β 

All interests and all short positions should be disclosed.

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental FormΒ 8 (Open Positions).

Β 

(b) Rights to subscribe for new securities (including directors' and other employee options)

Β 

Class of relevant security in relation to which subscription right exists:

Β 

Details, including nature of the rights concerned and relevant percentages:

Β 

Β 

Β 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

The currency of all prices and other monetary amounts should be stated.

Β 

(a) Purchases and sales

Β 

Class of relevant security

Purchase/sale

Β 

Number of securities

Price per unit

1p Ordinary

Sale

253,026

Β£1.410138

Β 

(b) Cash-settled derivative transactions

Β 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Β 

Β 

Β 

(c) Stock-settled derivative transactions (including options)

Β 

(i) Writing, selling, purchasing or varying

Β 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

Β 

(ii) Exercise

Β 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(d) Other dealings (including subscribing for new securities)

Β 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

Β 

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Β 

(c) Attachments

Β 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Β 

Β 

Date of disclosure:

11 May 2026

Contact name:

Tom Verlander

Telephone number*:

07784666203

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

Β 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

Β 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
RETFIFEAEFILLIR
Date   Source Headline
9th Jul 20251:06 pmRNSDirector/PDMR Shareholding
9th Jul 202512:36 pmRNSNet Asset Value(s)
8th Jul 202512:32 pmRNSNet Asset Value(s)
7th Jul 20253:42 pmRNSMonthly Factsheet
7th Jul 20251:08 pmRNSNet Asset Value(s)
4th Jul 202512:56 pmRNSNet Asset Value(s)
3rd Jul 202512:35 pmRNSNet Asset Value(s)
2nd Jul 20253:31 pmRNSNet Asset Value(s)
1st Jul 20252:22 pmRNSNet Asset Value
1st Jul 20257:00 amRNSTotal Voting Rights
30th Jun 20252:50 pmRNSDirector/PDMR Shareholding
30th Jun 202512:39 pmRNSNet Asset Value
27th Jun 202512:55 pmRNSNet Asset Value
26th Jun 202511:58 amRNSNet Asset Value
25th Jun 202512:07 pmRNSNet Asset Value
24th Jun 202512:27 pmRNSNet Asset Value
23rd Jun 20252:30 pmRNSHolding(s) in Company - Replacement
23rd Jun 20251:22 pmRNSNet Asset Value
20th Jun 20251:21 pmRNSNet Asset Value(s)
20th Jun 20259:36 amRNSBlock listing Interim Review
19th Jun 202511:43 amRNSNet Asset Value
18th Jun 202511:50 amRNSNet Asset Value
17th Jun 20252:16 pmRNSNet Asset Value
16th Jun 202512:31 pmRNSNet Asset Value
13th Jun 202512:07 pmRNSNet Asset Value
12th Jun 20251:09 pmRNSNet Asset Value
11th Jun 202512:31 pmRNSNet Asset Value
10th Jun 20251:40 pmRNSNet Asset Value
9th Jun 20251:26 pmRNSNet Asset Value
6th Jun 202511:32 amRNSNet Asset Value(s)
5th Jun 20251:49 pmRNSMonthly Factsheet
5th Jun 202511:32 amRNSNet Asset Value(s)
4th Jun 202512:39 pmRNSNet Asset Value
3rd Jun 20254:21 pmRNSIssue of Equity
3rd Jun 20251:01 pmRNSNet Asset Value
2nd Jun 20251:26 pmRNSNet Asset Value(s)
30th May 202512:12 pmRNSNet Asset Value(s)
29th May 20251:14 pmRNSNet Asset Value
29th May 20257:00 amRNSAnnual Financial Report
28th May 202512:34 pmRNSNet Asset Value(s)
28th May 202510:49 amRNSForm 8.3 - Benchmark Holdings plc
27th May 20251:43 pmRNSNet Asset Value
23rd May 20255:37 pmRNSHolding(s) in Company
23rd May 202511:56 amRNSNet Asset Value
22nd May 20251:00 pmRNSNet Asset Value(s)
21st May 20251:00 pmRNSHolding(s) in Company
21st May 202512:57 pmRNSNet Asset Value
20th May 202512:20 pmRNSNet Asset Value
19th May 202512:45 pmRNSNet Asset Value
16th May 20251:04 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.